Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.

about

Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.

Item

http://www.wikidata.org/entity/Q38230423

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.

@en

type

Item

label

Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.

@en

prefLabel

Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.

@en

P1476

Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications.

@en

P2093

Angela M Falco

http://www.w3.org/2001/XMLSchema#string

Ellen Sullivan

http://www.w3.org/2001/XMLSchema#string

Lisa C Smith

http://www.w3.org/2001/XMLSchema#string

P2860

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.

Multiple myeloma and renal failure.

The blood coagulation mechanism in multiple myeloma.

Myeloma of the central nervous system: strong association with unfavorable chromosomal abnormalities and other high-risk disease features.

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

P304

37-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25031979

http://www.w3.org/2001/XMLSchema#string

P932

4093373

http://www.w3.org/2001/XMLSchema#string